– USA, NY – Trellus Health plc (LON: TRLS) today announced the appointment of Co-Founder and Board member, Dr. Marla Dubinsky, as CEO with immediate effect, replacing Monique Fayad who is standing down as CEO.
About Dr. Marla Dubinsky
Marla Dubinsky, MD, is a Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Dubinsky received her medical degree from Queen’s University, Canada. She completed her pediatric residency at Alberta Children’s Hospital, Calgary, Canada, and her clinical fellowship in gastroenterology and nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She completed her research fellowship in IBD at Cedars-Sinai Medical Center in Los Angeles, CA, where she served as the Director of the Pediatric IBD Center before going to Mount Sinai as the Chief of Pediatric Gastroenterology and Nutrition at the Mount Sinai Kravis Children’s Hospital and Co-Director of the Susan and Leonard Feinstein IBD Clinical Center. Dr. Dubinsky is also the Co-Director of the IBD Preconception and Pregnancy Planning Clinic at Mount Sinai. She is the Co-Founder of Mi-Test Health, and Cornerstones Health which is a non-profit organization dedicated to enhancing and transforming communication between health care providers, patients, and industry partners through creative, comprehensive, and expert-based educational program.
Dr. Dubinsky has been engaged in inflammatory bowel disease clinical and translational research for over two decades. Dr. Dubinsky’s primary research focuses on developing predictive models and web-based decision support tools that integrate clinical and biomarkers to predict the natural history of IBD and response to therapy. She has a keen interest in personalized medicine in IBD and her research uncovers predictors of rapid disease progression with the goal of preventing complications by altering treatment plans. Dr. Dubinsky is the principal investigator of multiple large longitudinal cohorts including the Road to Prevention Multiplex Family Program at Mount Sinai with over 700 enrolled participants with a goal of using multi-omic data to predict the development of IBD in unaffected family members and co-investigator of the Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn’s Disease study and senior author on the manuscript presenting a model to predict the natural history of pediatric Crohn’s disease. Dr. Dubinsky is very committed to women’s reproductive health in IBD and in addition to her research in this field she is the Co-founder of WECARE in IBD, an organization dedicated to the health of women with IBD. She has lectured widely, both nationally and internationally, and has published in more than 260 peer-reviewed journals, including Gastroenterology, Lancet, JAMA, The Journal of Pediatric Gastroenterology and Nutrition, The journal of Crohn’s and Colitis, Inflammatory Bowel Diseases, and the American Journal of Gastroenterology.
About Trellus Health plc
Trellus Health is the first digital health company focused on the intersection of chronic physical conditions and mental health. Trellus Health integrates its proprietary resilience-based methodology with the technology, tools and team to deliver a whole-person technology-enhanced experience that results in relieving disease burden and promoting individual health behaviors that enable thriving in the face of a chronic condition. Through its TrellusElevate connected care platform and companion App, the company addresses both clinical and behavioral health together, in context, to improve outcomes and reduce healthcare costs for patients, employers, and the healthcare system.
The Company is initially focused on Inflammatory bowel disease, which includes the chronic incurable conditions of Crohn’s Disease and ulcerative colitis, but considers its approach to have potential utility and demand across many chronic conditions, including Irritable Bowel Syndrome.
For more information : https://trellushealth.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
